Somapacitan-beco
Brand names: Sogroya · Active ingredient: Somapacitan
In short: SOGROYA is indicated for the treatment of pediatric patients aged 2.5 years and older with: • Growth failure due to inadequate secretion of endogenous growth hormone (GH). • Short stature born small for gestational age (SGA) and with no catch-up growth by 2 years of age.
What is Somapacitan-beco used for?
SOGROYA is indicated for the treatment of pediatric patients aged 2.5 years and older with:
•
Growth failure due to inadequate secretion of endogenous growth hormone (GH).
•
Short stature born small for gestational age (SGA) and with no catch-up growth by 2 years of age.
•
Growth failure associated with Noonan syndrome (NS).
•
Idiopathic Short Stature (ISS).
SOGROYA is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD).
Somapacitan-beco dosage
•SOGROYA treatment should be supervised by a healthcare provider who is experienced in the diagnosis and management of pediatric patients with growth failure due to GHD, pediatric patients born SGA, pediatric patients with NS, pediatric patients with ISS and/or adults with GHD .
•SOGROYA should be administered by subcutaneous injection, once weekly, any time of the day, in the upper arms, thigh, abdomen or buttocks with weekly rotation of injection site.
•Inspect visually for particulate matter and discoloration. SOGROYA should be a clear to slightly opalescent and colorless to slightly yellow solution. If the solution is cloudy or contains particulate matter do not use.
•Advise patients to read the PATIENT INFORMATION and INSTRUCTIONS FOR USE leaflets enclosed with the SOGROYA prefilled pen.
•SOGROYA is available in 3 single-patient-use prefilled pens with 3 different dosing ranges (Table 1).
Table 1. Strength and Dosing Range of SOGROYA Prefilled Pens
Strength | Dose increments (mg) | Dose Delivery Range (mg)
5 mg/1.5 mL (3.3 mg/mL) | 0.025 | 0.025 to 2
10 mg/1.5 mL (6.7 mg/mL) | 0.05 | 0.05 to 4
15 mg/1.5 mL (10 mg/mL) | 0.1 | 0.1 to 8
•Perform fundoscopic examination before initiating treatment with SOGROYA to exclude preexisting papilledema. If papilledema is identified, evaluate the etiology and treat the underlying cause before initiating treatment with SOGROYA .
•GH Deficiency: Recommended dosage of SOGROYA is 0.16 mg/kg based on actual body weight once weekly for treatment-naïve patients and patients switching from daily growth hormone (somatropin).
•Small for Gestational Age (SGA), Noonan Syndrome (NS), and Idiopathic Short Stature (ISS): Recommended dosage of SOGROYA is 0.24 mg/kg based on actual body weight once weekly for treatment-naïve patients and patients switching from daily growth hormone (somatropin).
•Individualize dosage for each patient based on the growth response.
•When switching from daily human growth hormone to once-weekly SOGROYA, choose the preferred day for the weekly dose. Take the final dose of daily treatment on the day before (or at least 8 hours before) the first dose of SOGROYA.
•When switching from a weekly human growth hormone to once-weekly SOGROYA, continue once weekly dosing schedule.
•Assess compliance and evaluate other causes of poor growth such as hypothyroidism, undernutrition, advanced bone age, and antibodies to recombinant human growth hormone if patients experience failure to increase height velocity, particularly during the first year of treatment.
•Patients who were treated with SOGROYA for GH deficiency in childhood and whose epiphyses are closed should be reevaluated before continuing SOGROYA. …
How to take Somapacitan-beco — instructions & advice from the label
Advise patients and/or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
•Advise patients and/or caregivers to administer SOGROYA once weekly.
•
Hypersensitivity - Advise patients and/or caregivers that severe and/or serious systemic hypersensitivity reactions (anaphylaxis and angioedema) have been reported, and to seek prompt medical attention should an allergic reaction occur .
•
Neoplasms – Advise patients to report marked changes in skin pigmentation or changes in the appearance of preexisting nevi.
•
Glucose Intolerance/ Diabetes Mellitus – Advise patients that new onset pre- /diabetes mellitus or exacerbation of preexisting diabetes mellitus can occur and monitoring of blood glucose during treatment with SOGROYA may be needed.
•
Intracranial Hypertension - Advise patients to report to their healthcare provider any visual changes, headache, and nausea and/or vomiting.
•
Fluid Retention - Advise patients that fluid retention during SOGROYA replacement therapy may frequently occur. Inform patients of the clinical manifestations of fluid retention (e.g. …
Warnings & precautions
Do not take this medicine if: SOGROYA is contraindicated in patients with:
•Acute critical illness after open-heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure because of the risk of increased mortality with use of pharmacologic doses of SOGROYA .
•Hypersensitivity to SOGROYA or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin .
•Pediatric patients with closed epiphyses.
•Active malignancy .
•Active proliferative or severe non-proliferative diabetic retinopathy.
•Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea or have severe respiratory impairment due to risk of sudden death .
Increased mortality has been reported after treatment with somatropin in patients with acute critical illness due to complications following open-heart surgery, abdominal surgery and multiple accidental trauma, as well as patients with acute respiratory failure . The safety of continuing SOGROYA treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. SOGROYA is not indicated for the treatment of non-GH deficient adults.
Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropin. Inform patients and/or caregivers that such reactions are possible, and that prompt medical attention should be sought if an allergic reaction occurs. SOGROYA is contraindicated in patients with known hypersensitivity to somatropin or any excipients in SOGROYA .
Active Malignancy
There is an increased risk of malignancy progression with somatropin treatment in patients with active malignancy . …
Somapacitan-beco side effects
The following clinically significant adverse drug reactions are described elsewhere in the labeling:
•Increased mortality in patients with acute critical illness
•Severe hypersensitivity
•Increased risk of neoplasms
•Glucose intolerance and diabetes mellitus
•Intracranial hypertension
•Fluid retention
•Hypoadrenalism
•Hypothyroidism
•Slipped capital femoral epiphysis in pediatric patients
•Progression of preexisting scoliosis in pediatric patients
•Pancreatitis
•Lipohypertrophy/Lipoatrophy
•Sudden death in pediatric patients with Prader-Willi syndrome
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Pediatric Patients with GHD
SOGROYA 0.16 mg/kg/week was studied in a 52-week randomized, open-label, active-controlled, parallel-group clinical study in 200 treatment-naïve, prepubertal pediatric patients with growth hormone deficiency . Table 2 shows common adverse reactions that occurred in ≥5% of patients treated with either SOGROYA or somatropin in this trial.
Table 2. …
Drug interactions
Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with SOGROYA and instructions for preventing or managing them.
Table 7. Clinically Important Drug Interactions with SOGROYA
Replacement Glucocorticoid Treatment
Clinical Impact: | Microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. GH inhibits 11βHSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11βHSD-1 and serum cortisol. Initiation of SOGROYA may result in inhibition of 11βHSD-1 and reduced serum cortisol concentrations.
Intervention: | Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SOGROYA .
Examples: | Cortisone acetate and prednisone may be affected more than others because conversion of these drugs to their biologically active metabolites is dependent on the activity of 11βHSD-1.
Cytochrome P450-Metabolized Drugs
Clinical Impact: | Limited published data indicate that GH treatment increases cytochrome P450 (CP450)-mediated antipyrine clearance. …
About this medicine
Somapacitan-beco is a human growth hormone (hGH) analog with a single substitution in the amino acid backbone (L101C) to which an albumin-binding moiety has been attached. The albumin-binding moiety (side-chain) consists of an albumin binder and a hydrophilic spacer attached to position 101 of the protein. The protein part consists of 191 amino acids. Somapacitan-beco is produced in Escherichia coli by recombinant DNA technology. The molecular formula (including the albumin-binding moiety) is C1038H1609N273O319S9 and the molecular weight is 23305.10 g/mol, of which the albumin-binding moiety is 1191.39 g/mol.
Structural Formula:
SOGROYA (somapacitan-beco) injection is supplied as a sterile, clear to slightly opalescent and colorless to slightly yellow solution for subcutaneous use in a single-patient-use prefilled pen with a deliverable volume of 1.5 mL.
Each mL of SOGROYA 5 mg/1.5 mL prefilled pen contains 3.3 mg of somapacitan-beco, histidine (0.68 mg), mannitol (44 mg), phenol (4 mg), poloxamer 188 (1 mg), and Water for Injection, USP. The pH is approximately 6.8. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID eadd03b4-adc3-4b88-8a24-9d205c5b85aa. Read the full official label on DailyMed.